IBB - Aurinia Pharmaceuticals: Down 30% From Its High It Offers A Discounted De-Risked Multi-Billion Dollar Opportunity
- Aurinia’s voclosporin demonstrated exceptional Phase 3 trial results to treat Lupus Nephritis “LN”, a significant unmet medical need with blockbuster potential.
- Voclosporin’s PDUFA date is in January 2021 and Aurinia is prepared to commercialize the drug on its own in the U.S.; Ex-U.S. partnership is a major potential stock catalyst.
- Voclosporin may have potential in other indications, and Aurinia’s ophthalmic solution offers upside as a treatment for Dry Eye Syndrome.
- Management of Aurinia has deep experience in LN with a track record of successful M&A exits.
- With over $400M in cash, several upcoming catalysts, the stock off nearly 30% from its 52-week high, and a de-risked story, AUPH is a compelling Buy.
For further details see:
Aurinia Pharmaceuticals: Down 30% From Its High, It Offers A Discounted De-Risked Multi-Billion Dollar Opportunity